Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE-4: Prasugrel + Bivalirudin vs. Clopidogrel + Heparin in STEMI
NCT00976092Phase 4
Key facts
- Status
- Unknown
- Start
- Sep 2009
- Primary completion
- Feb 2014
- Countries
- 1
- Sponsor
- Deutsches Herzzentrum München
- Modality
- Peptides, Small Molecules
- Drugs
- prasugrelbivalirudin
- Conditions
- myocardial infarction (MI)
01
Overview
Phase 4, randomised, open-label trial of prasugrel and bivalirudin in myocardial infarction (MI), sponsored by Deutsches Herzzentrum München. Primary endpoint: Composite of all-cause death, recurrent MI, unplanned IRA revascularization, stroke, definite stent thrombosis or major bleeding at 30 days. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients with STEMI within 24 hours of symptom onset, excluding those with high bleeding risk, prior stroke, or cardiogenic shock.
04
Endpoints
Primary
Composite of all-cause death, recurrent MI, unplanned IRA revascularization, stroke, definite stent thrombosis or major bleeding
Beyond the preview
Go deeper on NCT00976092.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00976092.